E-DRUG: New Book: Equitable access to high cost pharmaceuticals
-----------------------------------------------------------------------------------
Dear E-druggers
I would like to introduce you to recently published book on access to high-cost medicines. The book can be accessed if you have an institutional subscription to science direct database.
Book information
Equitable Access to High-Cost Pharmaceuticals
Editor: Zaheer-Ud-Din Babar
https://www.elsevier.com/books/equitable-access-to-high-cost-pharmaceuticals/babar/978-0-12-811945-7
Paperback ISBN: 9780128119457
Imprint: Academic Press
Published Date: 21st February 2018
Page Count: 238
Description
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
Reviews
"Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges." — Aris Angelis, The London School of Economics and Political Science
CONTENT
Chapter 1
Access to High-Cost Medicines: An Overview
Syed Shahzad Hasan, Christine Y. Lu, Zaheer-Ud-Din Babar
Chapter 2
Health Technology Assessment
Jennifer A. Whitty
Chapter 3
High-Cost Medicines in England
Darrin Baines
Chapter 4
Managed Entry Agreements and High-Cost Medicines (European Perspective)
Claudio Jommi
Chapter 5
Setting a Public Health Agenda to Support Access to High-Cost Medicines
Inthira Yamabhai
Chapter 6
Human Rights and Intellectual Property for Universal Access to New Essential Medicines
Katrina Perehudoff, Ellen ’t Hoen
Chapter 7
Access to High Price Medicines in Portugal
Filipa Alves da Costa, Ana Paula Martins
Chapter 8
Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
Brendan Kwesiga, Anita Katharina Wagner, Morries Seru,Birna Trap
Chapter 9
Equitable Access to Biosimilars: An Overview
Khurram Rehman, Nadeem Irfan Bukhari, Zaheer-Ud-Din Babar
Chapter 10
Access to High-Cost Medicines in Europe
Sabine Vogler
Chapter 11
Access to High-Cost Medicines in Australia
Agnes Isabelle Vitry, Russell Shute
Chapter 12
Access to High-Cost Medicines in New Zealand
Louise E. Curley, Maree Jensen, Zaheer-Ud-Din Babar,
Sanya Ram
Chapter 13
Access to High-Cost Medicines in Wales
Alice Varnava, Sabrina Rind, Robert Bracchi, Karen Samuels, Philip A. Routledge, Dyfrig A. Hughes
Kind Regards
Zaheer
Zaheer-Ud-Din Babar, PhD
Professor in Medicines and Healthcare
Department of Pharmacy, University of Huddersfield, Queensgate, HD1 3DH
Huddersfield, United Kingdom
Zaheer Babar <Z.Babar@hud.ac.uk>